Albert Bourla, DVM, PhD

Dr. Albert Bourla is chairman and CEO of Pfizer. He leads Pfizer in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health. During his more than 25 years at Pfizer, he has held several senior global positions across a range of markets and disciplines. Before becoming CEO, he served as COO, overseeing commercial strategy, manufacturing and global product development. Previously, he served as group president of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. He also created the Patient and Health Impact group, dedicated to increasing patient access, demonstrating the value of Pfizer’s medicines and broader business model innovation. Prior to that, he was president and GM of the Established Products business. He is a Doctor of Veterinary Medicine with a Ph.D. from the Veterinary School of Aristotle University and began his Pfizer career in 1993 in the Animal Health division. In 2020, Dr. Bourla was ranked America’s top CEO in the pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of the Partnership for New York City, a vice president of the IFPMA, a trustee of the U.S. Council for International Business, and a director on multiple boards, including Pfizer Inc., the Pfizer Foundation, PhRMA and Catalyst.